Long-Term Outcomes of Patients with Papillary Thyroid Cancer Undergoing Remnant Ablation with 30 milliCuries Radioiodine

Background: The study considered the long-term outcome of patients with papillary thyroid carcinoma treated with 30 mCi radioiodine. Objective: The aims of this study were to define and compare the remission rates of papillary thyroid carcinoma ablated with 30 mCi 131I prepared by either thyroid hormone withdrawal (THW) or recombinant human thyrotropin (rhTSH; Thyrogen®), and to identify variables predictive of a favorable prognosis. Method: An observational study was conducted at an academic medical center and a comparative summary of six studies is presented. Three hundred and seventy patients (THW group, n = 203; rhTSH group, n = 167) were recruited from a prospectively managed registry. The mean follow-up was 9.3 years (range 5.1–15.8 years) in the THW group and 7.1 years (range 5.0–9.7 years) in the rhTSH group. The primary endpoint was the long-term remission rates (no evidence of disease) in the THW group compared with the rhTH group. Results: The response at 12–18 months after 30 mCi remnant ablat...